Srax, INC

SRAX Inc. has entered into a definitive merger agreement with DNA Holdings Venture Inc., which will result in DNA's shareholders becoming the majority owners of SRAX's outstanding common stock.

SRAX, Inc. has entered into a securities purchase agreement for a $90,000 convertible promissory note, with an original issue discount, resulting in $75,000 in funding.

SRAX Inc. has amended the terms of its Series B Preferred Stock, removing the need for shareholder approval for certain issuances and expanding trading market options.

SRAX, Inc. has entered into an agreement to issue a convertible promissory note for $75,000, with a principal amount of $90,000, convertible into common stock at $0.25 per share.

SRAX Inc. reports a substantial revenue decrease in Q2 2023 due to a shift to a cash-only payment model and the sale of its LD Micro subsidiary, alongside ongoing concerns about its ability to continue as a going concern.

SRAX Inc. announces a net income of $2.63 million for the quarter ended March 31, 2023, while navigating a transition to a cash-based revenue model and the divestiture of LD Micro, Inc.

SRAX Inc.'s annual report for 2022 highlights significant operating losses, a going concern warning from auditors, and substantial changes in the company's structure and operations.

A group of reporting persons, including Percy Rockdale LLC and Michael Gorzynski, have fully divested their beneficial ownership in SRAX, Inc. Class A Common Stock as of September 30, 2025.